We recently published a list of 10 Stocks That Analysts Think Will Go Up. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other stocks that analysts think will go up.
The S&P 500 index touched an all-time high this week as Mark Zuckerberg’s company’s 20-day streak finally came to an end, adding $320 billion to the company’s market cap. The semiconductor stocks once again drove the broader market. However, as the rally cools down, the focus is shifting back to Donald Trump’s tariffs. Automobiles, pharmaceuticals, and semiconductor companies are expected to be hit in the next wave of tariffs which has forced investors to rethink their strategies.
As investors and analysts try to figure out where the market is headed, some companies are more likely to go up in share price than others. We looked through the recent analyst upgrades and shortlisted 10 companies that are likely to go up according to analysts. We also looked at the factors driving this analyst optimism.
To come up with the list of 10 stocks that analysts think will go up, we only considered stocks with a market cap of at least $1 billion that were upgraded this week.
A physician and a patient having a discussion in a hospital about biopharmaceutical medicines.
Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) operates as a biopharmaceutical company that develops, discovers, and markets medicines. It offers Descovy, Truvada, Stribild, Biktarvy, Odefsey, Genvoya, Atripla, and Sunlencs products. The company collaborates with various companies including Dragonfly Therapeutics, Inc.; Merck Sharp & Dohme Corp., Janssen Sciences Ireland Unlimited Company; and Tentarix Biotherapeutics Inc. The company received a boost when Deutsche Bank upgraded the stock from Hold to Buy based on the company’s pipeline of HIV drugs. Earnings estimates were also increased from 2029 onwards.
GILD’s HIV treatment Biktarvy’s patent was supposed to expire after 2033. However, with its pipeline products, the company can now add approximately $19 billion to its revenues, significantly changing analyst projections. This optimism comes after the FDA put the company’s Lenacapavir treatment for HIV under priority review, setting a June 19 FDUFA date, which is essentially a deadline for the agency to approve or reject a new drug.
Deutsche Bank has accordingly upgraded the price target from $80 to $120, a significant 50% boost.
Gilead Sciences, Inc. (NASDAQ:GILD) is not on our latest list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 59 hedge fund portfolios held GILD at the end of the third quarter which was 62 in the previous quarter.
Overall, GILD ranks 1st on our list of stocks that analysts think will go up. While we acknowledge the potential of GILD as a leading AI investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as GILD but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.
